scholarly journals Structural and functional radiomics for lung cancer

Author(s):  
Guangyao Wu ◽  
Arthur Jochems ◽  
Turkey Refaee ◽  
Abdalla Ibrahim ◽  
Chenggong Yan ◽  
...  

Abstract Introduction Lung cancer ranks second in new cancer cases and first in cancer-related deaths worldwide. Precision medicine is working on altering treatment approaches and improving outcomes in this patient population. Radiological images are a powerful non-invasive tool in the screening and diagnosis of early-stage lung cancer, treatment strategy support, prognosis assessment, and follow-up for advanced-stage lung cancer. Recently, radiological features have evolved from solely semantic to include (handcrafted and deep) radiomic features. Radiomics entails the extraction and analysis of quantitative features from medical images using mathematical and machine learning methods to explore possible ties with biology and clinical outcomes. Methods Here, we outline the latest applications of both structural and functional radiomics in detection, diagnosis, and prediction of pathology, gene mutation, treatment strategy, follow-up, treatment response evaluation, and prognosis in the field of lung cancer. Conclusion The major drawbacks of radiomics are the lack of large datasets with high-quality data, standardization of methodology, the black-box nature of deep learning, and reproducibility. The prerequisite for the clinical implementation of radiomics is that these limitations are addressed. Future directions include a safer and more efficient model-training mode, merge multi-modality images, and combined multi-discipline or multi-omics to form “Medomics.”

2016 ◽  
Vol 102 (4) ◽  
pp. 1067-1073 ◽  
Author(s):  
Andrea Billè ◽  
Usman Ahmad ◽  
Kaitlin M. Woo ◽  
Kei Suzuki ◽  
Prasad Adusumilli ◽  
...  

CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 652A
Author(s):  
Farid Gharagozloo ◽  
Marc Margolis ◽  
Eric Strother ◽  
Barbara J. Tempesta

2021 ◽  
Vol 11 ◽  
Author(s):  
Ran Zhang ◽  
Yanling Guo ◽  
Yujie Yan ◽  
Yuanjun Liu ◽  
Yaoyao Zhu ◽  
...  

PurposeStereotactic body radiotherapy (SBRT) has been increasingly regarded as a reasonable option for early-stage lung cancer patients without pretreatment pathologic results, but the efficacy and safety in a Chinese population remains unclear. The aim of this study was to compare survival outcomes and toxicities between patients with clinically diagnosed early-stage lung cancer or biopsy-proven early-stage non-small cell lung cancer and to demonstrate the rationality of this treatment.Material and MethodsFrom May 2012 to December 2018, 56 patients with clinically diagnosed early-stage lung cancer and 60 patients with early-stage biopsy-proven were selected into non-pathological group and pathological group, respectively. Propensity score matching (PSM) was performed to reduce patient selection bias. Survival analysis with log-rank test was used to assess the differences of treatment outcomes, which included local control (LC), progression-free survival (PFS), and overall survival (OS).ResultsThe median age was 76 (range 47–93) years, and the median follow-up time was 58.3 (range 4.3–95.1) months in the cohort without pathologic results. The median age was 74 (range 57–88) years, and the median follow-up time was 56.3 (range 2.6–94) months in the cohort with pathologic results. 45 matched-pair were analyzed. The 5-year LC, PFS, and OS rates in matched-pair patients with or without pathologic biopsy were 85.5% and 89.8%, 40.6% and 70.9%, and 63.2% and 76.1%, respectively. On Kaplan-Meier survival analysis after PSM analysis, there was no significant difference between patients with pathologic results versus patients with no pathologic results in terms of LC (P= 0.498) and OS (P=0.141). Of the matched-pair patients treated with SBRT, only 1 patient experienced grade 3 or above radiation pneumonitis.ConclusionFor early-stage lung cancer patients with medically inoperable or not suitable for invasive diagnosis, SBRT may be a good local treatment.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7520-7520 ◽  
Author(s):  
Suresh Senan ◽  
Kitty Huang ◽  
Sashendra Senthi ◽  
Femke Spoelstra ◽  
Andrew Warner ◽  
...  

7520 Background: Stereotactic ablative radiotherapy (SABR) is a guideline-recommended treatment for unfit patients with early-stage lung cancer. The 5-year local recurrence rates are approximately 10% but fibrotic changes are common during follow-up, leading to difficulty with timely detection and salvage therapies. Previously reported high-risk features (HRFs) on computed tomography (CT) are 1) enlarging opacity at the primary site; 2) sequential enlarging opacity; 3) enlarging opacity after 12 months; 4) bulging margin; 5) loss of linear margin and 6) loss of air bronchograms. We performed a blinded assessment of CT imaging of patients with and without local recurrences. Methods: Patients treated with SABR for early stage lung cancer between 2003 and 2012, who developed pathology-proven local recurrence (n=12), were matched 1:2 to patients without recurrences (n=24), based on baseline factors. The median age at diagnosis was 68 years and median post-SABR imaging follow-up was 24 months (range 6 to 67 months). Patients were well-matched in the recurrence and non-recurrence groups. A total of 153 CT scans were available. Serial CT images were assessed by 3 radiation oncologists blinded to outcomes, viewing anonymized images projected onto a large screen. Results: All established HRFs were significantly associated with local recurrence (p<0.01), and one additional HRF was identified: cranio-caudal growth (p<0.001). The best individual predictor of local recurrence was opacity enlargement after 12 months(100% sensitivity, 83% specificity, p<0.001). The odds of recurrence increased 4-fold for each additional HRF detected in an individual patient. The presence of ≥3 HRFs in an individual patient was highly sensitive and specific for recurrence (both >90%). The HRFs enlarging opacity and cranio-caudal growth were each detected ≥3 months prior to the actual diagnosis of local recurrence in 42% of patients. Conclusions: Local recurrences following SABR can be accurately predicted by the presence of HRF’s on post-treatment CT scans. This approach may reduce unnecessary diagnostic procedures, and ensure earlier use of salvage therapies.


2021 ◽  
Vol 16 (3) ◽  
pp. S264-S265
Author(s):  
F. Xu ◽  
L. Yang ◽  
C. Liu ◽  
J. Ying ◽  
Y. Wang

Sign in / Sign up

Export Citation Format

Share Document